Rady Children’s Shows Genomic Sequencing for Infants in Intensive Care Yields Life-Changing Benefits and Medical Cost Savings
State funded Medi-Cal pilot completed at 5 Children’s Hospitals Statewide In a pilot program funded by the State of California, Rady Children’s Hospital-San Diego demonstrated that a rapid precision medicine program for critically ill babies enrolled in Medi-Cal produced better health outcomes and reduced suffering for the infants while decreasing the cost of their care.
San Diego’s Scientific and Medical Institutes Collaborate on Large-scale Research Program to Study Spread of COVID-19
A consortium that includes many of San Diego’s top medical and scientific research institutes has launched a large-scale COVID-19 screening effort to better understand the spread and prevalence of the virus in the local community, with an initial focus on evaluating healthcare workers and first responders.
Scientists identify promising immunotherapy combination for pediatric brain cancer
Plan Will Cover Whole Genome Sequencing for Ill Children
Blue Shield of California has agreed to cover rapid and ultra-rapid whole genome sequencing for critically ill infants and children in intensive care who have unexplained medical conditions. The agreement — which will use testing at Rady Children’s Institute for Genomic Medicine, a center of excellence in genetic testing — likely will spur additional insurers […]
Blue Shield of California Becomes First Health Plan in U.S. to Cover Cost of Rapid Whole Genome Sequencing for Critically Ill Children
Innovative genetics solution pioneered by Rady Children’s Institute for Genomic Medicine; Eligible children are covered by parents’ health plan OAKLAND and SAN DIEGO, Calif. (March 9, 2020) – Blue Shield of California has become the first health plan in the United States to cover rapid and ultra-rapid Whole Genome Sequencing to help critically ill babies […]
23 and Baby
SCIENTIFIC AMERICAN: We now have the ability to screen for thousands of genetic diseases in newborns.
2019: A Watershed Year for Genomics in Clinical Care
Illumina CEO Francis deSouza opines that “2019 may well be remembered as the start of a new era of treatment for patients with genetic disease” and reflects on the significant advance seen in the past year.